Table 5 Multivariable Cox regression analysis for progression-free survival.

From: Prognostic significance of cachexia index in patients with advanced hepatocellular carcinoma treated with systemic chemotherapy

 

Univariable analysis

Multivariable analysis

HR (95% CI)

p-value

HR (95% CI)

p-value

Age ≥ 60 (vs. < 60), years

0.77 (0.48, 1.25)

0.77

  

Male (vs. female)

1.03 (0.53, 2.02)

0.93

  

ECOG ≥ 1 (vs. 0)

0.84 (0.38, 1.84)

0.66

  

BMI < 20 kg/m2 (≥ 20 kg/m2)

1.90 (1.01, 3.59)

0.05

1.83 (0.96, 3.49)

0.07

Etiology (VH vs. non-VH)

1.19 (0.66, 2.16)

0.56

  

History of previous treatmenta

1.21 (0.70, 2.08)

0.49

  

Maximal tumor diameter ≥ 10 cm

1.00 (0.58, 1.75)

0.99

  

Intrahepatic lesion

1.52 (0.80, 2.91)

0.20

1.34 (0.68, 2.63)

0.40

Extrahepatic metastases

1.05 (0.59, 1.87)

0.86

  

Portal vein involvement

1.06 (0.65, 1.73)

0.83

  

AFP ≥ 400 ng/mL (< 400 ng/mL)

1.83 (1.12, 2.99)

0.02

1.80 (1.10, 2.95)

0.02

PIVKA-II ≥ 400 mAU/mL (< 400 mAU/mL)

0.79 (0.49, 1.29)

0.35

  

mALBI grade ≥ 2b (vs. < 2b)

1.46 (0.72, 2.97)

0.29

  

Low CXI (vs. High CXI)

2.14 (1.31, 3.50)

0.003

1.84 (1.09, 3.09)

0.02

  1. HR: hazard ratio; CI: confidence interval; ECOG: Eastern Cooperative Oncology Group; BMI: body mass index; VH: viral hepatitis; BCLC: Barcelona Clinic Liver Cancer; AFP: alpha-fetoprotein; PIVKA-II: Protein Induced by Vitamin K Absence or Antagonist-II; mALBI grade: modified ALBI grade; CXI: cancer cachexia index.
  2. aDefined treatment history of resection, liver transplantation, radiofrequency ablation, transarterial chemoembolization, transarterial radioembolization and radiation therapy.
Back to article page